BioSpace News Archive

Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million 1 and consolidated cash, cash equivalents and short-term investments of $350.1 million, 2 as of December 31, 2022.

Cybin Inc. today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 26th Annual Milken Institute Global Conference on a panel entitled “Progress and Innovation: The Dawning of a New Day in Treating Mental Health.”

Which YouTube videos can you trust talking about penile augmentation? Has the average size of a penis increased? Are there meaningful differences in drug choice for men with coronary artery disease and erectile dysfunction?

What is MV140 and how does it help prevent rUTI? How many women experience financial toxicity when getting treated for urinary incontinence?

LAMF Global Ventures Corp I announced today that they have entered into a non-binding letter of intent (the “LOI”) for a proposed business combination.

2seventy bio, Inc. will announce its first quarter 2023 financial results on Wednesday, May 3, 2023.

Digital health start-up h2o Therapeutics today announced a collaboration with global healthcare company AmerisourceBergen to support the commercialization of Parky, a prescription mobile app cleared by the U.S. Food and Drug Administration (FDA) for monitoring certain symptoms in adults with Parkinson’s Disease.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq.

There might be a new, non-pharmacological way to treat major mental health disorders like schizophrenia spectrum disorders and psychosis.

Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer